DRUG
Eloralintide
Administered SC
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Status
Recruiting
Phase
Phase 3
Enrollment
900
Locations
173
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.
Interventions
Treatment arms and agents.
DRUG
Placebo
Administered SC
Timeline
From registration to results.
First posted
Feb 6, 2026
Study start
Feb 10, 2026
Primary completion
Jun 2028
Study completion
Jul 2028
Results posted
Not reported
Registry updated
Jul 17, 2026
Outcomes
What the study measures.
Primary outcomes
Percent Change from Baseline in Body Weight
Time frame · Baseline, Week 64
Secondary outcomes
Change from Baseline in Waist Circumference
Time frame · Baseline, Week 64
Percent Change in Baseline in Triglycerides
Time frame · Baseline, Week 64
Change from Baseline in Systolic Blood Pressure
Time frame · Baseline, Week 64
Change from Baseline in Body Mass Index (BMI)
Time frame · Baseline, Week 64
Change from Baseline in Fasting Glucose in Participants with Type 2 Diabetes at Baseline
Time frame · Baseline, Week 64
Change from Baseline in Short Form-36 (SF-36 v2) Score
Time frame · Baseline, Week 64
Change from Baseline in EQ-5D-5L Score
Time frame · Baseline, Week 64
Change from Baseline in Control of Eating Questionnaire (CoEQ) Score
Time frame · Baseline, Week 64
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) Physical Function Weight
Time frame · Baseline, Week 64
Percent Change from Baseline in Fasting Insulin
Time frame · Baseline, Week 64
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Are on stable incretin therapy at screening * With persistent obesity or overweight defined as: * ≥30 kg/m2 OR * ≥27 kg/m2 with at least one existing obesity related complication at screening: * hypertension * dyslipidemia * obstructive sleep apnea * cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or * type 2 diabetes * Have a stable body weight (\<5% body weight change) at screening Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes * Have taken any of the following antihyperglycemic medications within 90 days before screening: * dipeptidyl peptidase-4 (DPP-4) inhibitors * amylin analogs * insulin * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
Study locations
173 registered sites.
Australia · Belgium · Brazil · China · Czechia · Israel · Japan · Mexico · Puerto Rico · Romania · Spain · Taiwan · United States. Showing up to 24 locations stored in the fast local snapshot.
Birmingham Clinical Research
Birmingham, Alabama, United States
RIO Clinical Trials - Phoenix
Phoenix, Arizona, United States
Headlands Research - Scottsdale
Scottsdale, Arizona, United States
Novak Clinical Research - Tucson - North La Cholla Boulevard
Tucson, Arizona, United States
Irvine Clinical Research
Irvine, California, United States
Scripps Whittier Diabetes Institute
La Jolla, California, United States
EndoTrials Center for Clinical Research
La Mesa, California, United States
Peninsula Research Associates
Rolling Hills Estates, California, United States
Care Access - Sacramento
Sacramento, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
Southern California Clinical Research
Santa Ana, California, United States
University Clinical Investigators, Inc.
Tustin, California, United States
New England Research Associates, LLC
Bridgeport, Connecticut, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
JEM Research Institute
Atlantis, Florida, United States
AMR Clinical
Doral, Florida, United States
Northeast Research Institute (NERI)
Fleming Island, Florida, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
New Horizon Research Center
Miami, Florida, United States
St Johns Center for Clinical Research
Saint Augustine, Florida, United States
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States
Teak Research Consults - Dunwoody
Dunwoody, Georgia, United States
Center for Advanced Research & Education
Gainesville, Georgia, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Eloralintide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 1
Not yet recruiting
56
2026-07
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly · Obesity · Overweight
Phase 2
Active, not recruiting
367
2026-07
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
200
2026-07
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly · Overweight · Obesity
Phase 3
Recruiting
1,035
2026-07
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Eli Lilly · Obesity · Overweight
Phase 3
Recruiting
1,980
2026-07
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Eli Lilly · Osteoarthritis · Overweight or Obesity
Phase 3
Recruiting
900
2026-07
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly · Sleep Apnea, Obstructive · Obesity
Phase 3
Recruiting
800
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.